Drug Profile
Research programme: multi-specific antibody capsid products - Bullet Biotechnology
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Bullet Biotechnology
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Cancer in USA
- 08 Jul 2016 Research programme: multi-specific antibody capsid products - Bullet Biotechnology is available for licensing as of 08 Jul 2016. http://www.bulletbio.com
- 05 Jul 2016 Early research in Cancer in USA (unspecified route)